Clinical Evidence - Type 2 Diabetes

Podcast Episode 27: How Dexcom Real-Time CGM Supports Pregnant Patients and Enhances Diabetes Management

Podcasts

Yes

Related Resources

Podcast Episode 26: Type 2 Diabetes Management with CGM (ATTD)

Premium Content

Off

Podcast Episode 26: Type 2 Diabetes Management with CGM (ATTD)

alexa.stelzer — Thu, 12 Jun 2025 17:38:36 +0000

Podcast Episode 26: Type 2 Diabetes Management with CGM (ATTD)

05/06/2025

alexa.stelzer Thu, 06/12/2025 - 17:38

Advanced Technologies & Treatments for Diabetes Conference

Guest Speakers: Sim Singh, Senior Director of Behavioral and Translational Science at Dexcom

Real-Time Real Talk is intended for healthcare professionals in the US.

In this episode of Real-Time Real Talk, host Cher Pastore is joined by Sim Singh, Senior Director of Behavioral and Translational Science at Dexcom, to explore new research presented at the Advanced Technologies & Treatments for Diabetes (ATTD) conference. The discussion includes:

Finding from a 30-day study on Dexcom G7 use in people with type 2 diabetes, including those not on insulin.
Behavioral and metabolic improvements, especially among CGM-naive users.
How CGM empowers patients and providers through real-time data, personalized care, and increased confidence.
Highlights from a Canadian trial on CGM's impact on mindset, motivation, and daily habits.

Listen to the full episode here – available on Apple Podcasts and Spotify. Subscribe to never miss an episode!

^MAT-9578

Podcast

ATTD 2025 - Revolutionizing Type 2 Diabetes Care with the Latest Innovations in Dexcom Technology

Podcasts

Yes

Related Resources

ATTD 2025 - Dexcom CGM: All Ages All Stages of Diabetes

Premium Content

Off

Happy Bob Turns Real-Time Health Data into Engaging Experiences

alexa.stelzer — Wed, 19 Mar 2025 15:40:50 +0000

Happy Bob Turns Real-Time Health Data into Engaging Experiences

04/08/2025

alexa.stelzer Wed, 03/19/2025 - 15:40

Digital Health Apps Enhancing Diabetes Management

Discover how Happy Bob empowers healthcare providers to revolutionize diabetes care with innovative tools for patient self-care, remote monitoring, and revenue optimization.

Meet Happy Bob

Happy Bob is a digital health app designed to empower healthcare providers, physician groups, clinics, and the patients they serve. With the goal of reducing the stress that comes with diabetes data overload, Happy Bob turns Dexcom CGM into an engaging experience, with personalities, awards, and notifications that help keep glucose in range while reducing the mental toll.^1,2*†

Key Features of Happy Bob Smartphone App

The Happy Bob smartphone app offers a variety of features to support patients and their care teams. Features include:

Notifications of real-time glucose values and trends delivered with fun, personalized messages
Ability to set goals, track progress, and earn starts when glucose is in range
Home screen widget displaying real-time glucose
Multiple "diabuddy” personalities to choose from including Happy Bob, Snarky Bob, and Karen
Group feature allows connections with other users
Sharing feature allows caregivers to view data and achievements
Scoreboard with personal statistics

Happy Bob's Provider-Focused Dashboard

Happy Bob also offers an easy-to-use dashboard for healthcare providers and care teams, enabling remote patient monitoring and streamlining clinic workflows. The comprehensive dashboard is designed to help providers quickly assess patient trends, view simplified health data visualizations, and access custom reports that save time and enhance diabetes management. Happy Bob’s advanced service offerings are designed to be a flexible, scalable solution that advance patient care, save time, and generate new revenue streams for clinics.

Recent and Future Research

Data presented at the 2024 International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) found that after 28 days of Happy Bob and Dexcom CGM use, children ≥ 12 years old with type 1 diabetes experienced on average a 10.5% increase in time in range (TIR) (n=14, avg baseline TIR 37.7%, p=0.0002).² The abstract noted that future research will be focused on the impact of the app functionality alongside a patient monitoring program.²

Compatibility and Integrations

Happy Bob is an FDA Class 2 Exempt device and available on both iOS and Android. As a Dexcom Real-Time Data Partner, Happy Bob integrates with Dexcom G7 and Dexcom G7 CGM systems. Users can sync with Apple Health and Google Health as well as connect their Apple Watch to see Happy Bob notifications directly from their smartwatch. While Happy Bob does not currently offer integration with electronic health records (EHR) systems, both patients and providers are able to login to the desktop dashboard to view data on their desktop computer.

For more information about Happy Bob, book a free demo on the Happy Bob site.

To learn more about digital health apps revolutionizing diabetes management, explore Dexcom’s Digital Health Hub.

^{1. Happy Bob™. Accessed August 20, 2024. https://happybob.app.}

^{2. MacColl et al, Youth with T1D improve TIR by use of a relational agent embedded in a smart phone app. Poster presented at ATTD 2024, Florence, Italy.}

^{*Compatible smart devices sold separately. To view a list of compatible devices, visit the link in bio. Digital Health apps are a third-party platform that is not intended to serve as a replacement for a primary display device for a continuous glucose monitoring system.}

^{†Happy Bob app is intended to be used as a secondary display for Dexcom CGM to notify the user of their CGM sensor glucose information in real time. The secondary display is intended for providing secondary notification of a continuous glucose monitoring system and does not replace primary real time continuous glucose monitoring or standard home blood glucose monitoring.}

^{BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available a https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.}

^MAT-8240

Clinical Evidence - Type 1 Diabetes

Introducing Dexcom's Digital Health Hub

Related Resources

Stelo: Personalizing Choices, Revolutionizing Glucose Health Presented by Patrick Welch, PharmD, BCACP

Premium Content

Podcast Episode 24: Type 2 Diabetes Management Through Glucose Tracking

alexa.stelzer — Mon, 10 Mar 2025 19:35:23 +0000

Podcast Episode 24: Type 2 Diabetes Management Through Glucose Tracking

03/19/2025

alexa.stelzer Mon, 03/10/2025 - 19:35

How CGM Improves Patient Outcomes

Guest Speakers: Dr. Thomas Grace & Dr. William Polonsky

Real-time real talk is intended for healthcare professionals in the US.

In this episode of Real Time Real Talk, host Cher Pastore is joined by Dr. Thomas Grace and Dr. William Polonsky to discuss the power of continuous glucose monitoring (CGM) in managing type 2 diabetes. The discussion includes:

Recent research on patient outcomes with the use of CGM
Benefits of CGM for making informed dietary and lifestyle choices
Psychological effects of CGM use
Introduction of Dexcom's over-the-counter product, Stelo

To learn more about Stelo, visit www.Stelo.com .

^MAT-8098

Podcast

Stelo: Personalizing Choices, Revolutionizing Glucose Health

Podcasts

Yes

Thomas Grace, MD, CDCES

Thomas Grace is a Family Medicine doctor in Findlay, Ohio. Dr. Grace and is rated as a Distinguished doctor by MediFind in the treatment of Type 2 Diabetes (T2D). He is also highly rated in 2 other conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Sepsis, Type 1 Diabetes (T1D), and Pacemaker Implantation.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 1 clinical trial in the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Type 2 Diabetes (T2D).

William H. Polonsky, PhD, CDCES

Dr. Polonsky is President and Founder of the Behavioral Diabetes Institute, the world's first organization wholly dedicated to studying and addressing the unmet psychological needs of people with diabetes. He is also Associate Clinical Professor in Psychiatry at the University of California, San Diego. Dr. Polonsky received his PhD in clinical psychology from Yale University and has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators.

Related Resources

Podcast Episode 23: Charting a New Path: How Glucose Sensors are Driving Behavior Change in Prediabetes and Type 2 Diabetes

Premium Content

Off

Stelo: Personalizing Choices, Revolutionizing Glucose Health Presented by Patrick Welch, PharmD, BCACP

alexa.stelzer — Thu, 20 Feb 2025 15:48:55 +0000

Stelo: Personalizing Choices, Revolutionizing Glucose Health Presented by Patrick Welch, PharmD, BCACP

03/13/2025

alexa.stelzer Thu, 02/20/2025 - 15:48

About the Webinar

In this 43-minute session, Patrick Welch, PharmD, BCACP, provides an introduction to Stelo and key takeways for pharmacists and other healthcare providers.

Key Highlights:

[1:27] The Dexcom portfolio: Discover the differences between Dexcom G7 CGM and Stelo and how to choose the right product for your patients

[7:16] Glucose management matters: Explore why managing glucose levels is important for patients with type 2 diabetes and prediabetes

[13:14] Introducing Stelo: Learn about the innovative functionality of Stelo

[15:47] Case Study: Explore how Stelo impacts decision making and outcomes in a patient with type 2 diabetes

[17:18] Key Stelo features: Deep dive into Stelo's unique features and how they promote behavior change

[33:09] Emerging clinical evidence in T2D: Review recent evidence exploring how glucose monitoring can improve diabetes outcomes

[39:12] Getting started: Learn how to help patients get started on Stelo

About Stelo by Dexcom

Stelo marks a significant advancement in glucose monitoring. As the first FDA-cleared OTC glucose biosensor, it provides an option for those who do not have insurance coverage for CGM. With Stelo, patients can monitor their glucose levels and time spent in their target range, enabling informed decisions about their health and lifestyle.

Learn More About Stelo

Don’t miss out on this valuable opportunity to enhance your practice and improve patient care. Learn more at Stelo.com.

^Keywords^{: Stelo, glucose biosensor, glucose monitoring, prediabetes, type 2 diabetes, Dexcom, patient empowerment, primary care, glucose health webinar}
^MAT-7831

New Video Series: Your Journey with Stelo Towards Glucose Health

Yes

Patrick Welch, PharmD, BCACP

Dr. Welch is an Advanced Clinical Pharmacist specializing in Family Medicine. After graduating from the University of Utah College of Pharmacy, he completed a two year ambulatory care pharmacy residency. Dr. Welch currently works in Family Medicine managing chronic disease states under collaborative practice agreements. He spends most of his time helping people living with diabetes including management of insulin pump therapy and CGM. He enjoys using the latest technology to help patients live their healthiest lives.

Related Resources

Podcast Episode 23: Charting a New Path: How Glucose Sensors are Driving Behavior Change in Prediabetes and Type 2 Diabetes

Premium Content

Off

Podcast Episode 23: Charting a New Path: How Glucose Sensors are Driving Behavior Change in Prediabetes and Type 2 Diabetes

alexa.stelzer — Mon, 13 Jan 2025 18:05:46 +0000

Podcast Episode 23: Charting a New Path: How Glucose Sensors are Driving Behavior Change in Prediabetes and Type 2 Diabetes

02/11/2025

alexa.stelzer Mon, 01/13/2025 - 18:05

Guest Speaker: Emily Cornelius, RDN

Real-time real talk is intended for healthcare professionals in the US.

In this episode of Real Time Real Talk, host Cher Pastore is joined by Registered Dietitian Emily Cornelius to discuss the science behind monitoring glucose levels in individuals with prediabetes and type 2 diabetes. The discussion includes:

Impact of glucose sensors on behavior change
Importance of personalized nutrition plans
Accessibility of glucose sensors without a prescription
Introduction of Dexcom's new product, Stelo

To learn more about Stelo, visit www.Stelo.com .

^MAT-7567

Podcast

Stelo: Personalizing Choices, Revolutionizing Glucose Health

Podcasts

Yes

Related Resources

New Video Series: Your Journey with Stelo Towards Glucose Health

Premium Content

Off

Stelo: Personalizing Choices, Revolutionizing Glucose Health Presented by Rachael Sood NP-C, CDCES

alexa.stelzer — Thu, 10 Oct 2024 18:57:07 +0000

Stelo: Personalizing Choices, Revolutionizing Glucose Health Presented by Rachael Sood NP-C, CDCES

10/18/2024

alexa.stelzer Thu, 10/10/2024 - 18:57

Webinar Featuring Rachael Sood RN, MSN, NP-C, CDCES

Watch the recording of Rachael Sood RN, MSN, NP-C, CDCES, as she presents "Stelo: Personalizing Choices, Revolutionizing Glucose Health".

About the Webinar

In this 56-minute session, Rachel Sood, provides an introduction to Stelo and key takeways from the perspective of a Diabetes Nurse Practitioner. Stelo is the first FDA-cleared OTC glucose biosensor and tailored for patients with prediabetes or type 2 diabetes not on insulin.

Key Highlights:

[02:24] The Dexcom portfolio: Discover the differences between Dexcom G7 CGM and Stelo and how to choose the right product for your patients

[11:32] Glucose management matters: Explore why managing glucose levels is important for patients with type 2 diabetes and prediabetes

[20:17] Introducing Stelo: Learn about the innovative functionality of Stelo

[23:46] Case Study: Explore how Stelo impacts decision making and outcomes in a patient with type 2 diabetes

[25:07] Key Stelo features: Deep dive into Stelo's unique features and how they promote behavior change

[47:10] Emerging clinical evidence in T2D: Review recent evidence indicating that glucose monitoring devices can improve diabetes outcomes

[53:32] GLP-1 medications and CGM: Highlights the benefits of using a Dexcom CGM in combination with GLP-1 medications

[54:35] Getting started: Learn how to help patients get started on Stelo

About Stelo by Dexcom

Stelo marks a significant advancement in glucose monitoring. As the first FDA-cleared OTC glucose biosensor, it provides an option for those who do not have insurance coverage for CGM. With Stelo, patients can monitor their glucose levels and target range, enabling informed decisions about their health and lifestyle.

Learn More About Stelo

Don’t miss out on this valuable opportunity to enhance your practice and improve patient care. Learn more at Stelo.com.

^Keywords^{: Stelo, glucose biosensor, glucose monitoring, prediabetes, type 2 diabetes, Dexcom, patient empowerment, primary care, glucose health webinar}

Seeing is Believing: Sustained Behavior Change Powered by Dexcom

Yes

Rachael Sood, RN, MSN, NP-C, CDCES

Rachael Sood, RN, MSN, NP-C, CDCES, is a diabetes nurse practitioner in Mandeville, Louisiana. She is the owner and operator of The Diabetes Collective, the first and only dedicated diabetes clinic in southern Louisiana, providing full-service specialized diabetes care. Ms. Sood’s business was launched in an effort to bring advanced diabetes care to her hometown using direct care models, technology integration, and updated practice tools and techniques that the rural region had never seen. She also serves as a nursing instructor for the Louisiana State University School of Nursing and was honored in 2024 by the Louisiana State Nurses Association as one of the top "40 under 40" trailblazing nurses recognized for revolutionizing patient care, driving innovations, and inspiring their peers. Ms. Sood is board certified by the American Academy of Nurse Practitioners and is a certified diabetes care and education specialist.

Related Resources

Premium Content

Off

EASD 2024 Hot Topics: The Value of Patient Empowerment in a Socioeconomically Deprived Population

alexa.stelzer — Wed, 09 Oct 2024 20:08:10 +0000

EASD 2024 Hot Topics: The Value of Patient Empowerment in a Socioeconomically Deprived Population

10/09/2024

alexa.stelzer Wed, 10/09/2024 - 20:08

Tackling Clinical Inertia in Type 2 Diabetes with Dexcom CGM

About the Presentation

The presentation covers a real-world study in Sheffield, England, on the use of the Dexcom Continuous Glucose Monitoring (CGM) system for patients with type 2 diabetes. The study aimed to assess the impact of CGM on HbA1c levels, quality of life, and diabetes management, particularly in a socially deprived population.

Key Takeaways:

The study presented suggests that:

Using CGM technology can lead to significant and sustained reductions in HbA1c levels
Patients using CGM reported enhanced quality of life and reduced diabetes-related distress
CGM technology enabled patients to make more informed decisions about their insulin use and dietary habits, promoting better self-management.

Highlights

00:00:35 - Study overview and recruitment criteria
00:04:30 - Patient-reported outcomes and quality of life improvements
00:05:30 - HbA1c results and significance
00:06:54 - Discussion on weight changes and insulin regimen adjustments
00:10:30 - Behavior change related to CGM
00:18:24 - Summary of findings and key takeaways

^{The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.}
^{The information you see or hear at this event provides details about medical products which are not available in all countries, may have different indications, and/or have not received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing shown or stated herein should be construed as a solicitation, advertisement, or promotion of any product, or of an indication of any specific use for any product, which is not authorized by the laws and regulations of the country where you reside.}

EASD 2024 Hot Topics: The Value of Patient Engagement in the Light of Modern Treatments

Yes

Related Resources

Premium Content

New Episodes Alert: Beyond the Bolus Podcast

alexa.stelzer — Mon, 30 Sep 2024 21:36:43 +0000

New Episodes Alert: Beyond the Bolus Podcast

10/01/2024

alexa.stelzer Mon, 09/30/2024 - 21:36

Explore Innovations in Diabetes Technology with Omnipod’s Beyond the Bolus Podcast

Discover the latest episodes of Omnipod’s Beyond the Bolus podcast! Featuring expert insights on Omnipod 5 and Dexcom G7 integration with Dr. Pablo Mora, and the future of Type 2 diabetes care with Dr. Viral Shah. Stay ahead with actionable advice and industry trends. Listen now to enhance your practice!

We are thrilled to announce the release of brand-new episodes of Beyond the Bolus, Omnipod’s podcast tailored for healthcare professionals. These episodes feature healthcare providers from a variety of backgrounds and specialties and explore the latest in diabetes technology, clinical data and more. Recent episodes include:

Omnipod 5 with Dexcom G7 Integration is Here!: Join Dr. Pablo Mora as he delves into the seamless integration of Omnipod 5 with Dexcom G7. Learn about the benefits of this integration and how it can simply diabetes management for your patients.
Unlock the Future of Type 2 Diabetes Care: Dr. Viral Shah shares his insights on the evolving landscape of type 2 diabetes care. Discover emerging trends, innovative treatments, and strategies to improve patient outcomes.

Whether you’re looking to stay ahead of the latest trends or seeking practical advice from industry leaders, these episodes are packed with valuable content to enhance your practice.

Stay connected, stay informed, and continue to provide the best care for your patients with Beyond the Bolus.

Listen here or using the player below.

Podcast

Clinical Evidence - Automated Insulin Delivery

Clinical Evidence - Type 1 Diabetes

Innovations for the Omnipod® 5 System: A Guide for Healthcare Providers

Related Resources

Podcast Episode 21: Clinical Accuracy in CGM and Why It Matters

Premium Content

Off

EASD 2024 Hot Topics: The Value of Patient Engagement in the Light of Modern Treatments

alexa.stelzer — Fri, 20 Sep 2024 14:06:40 +0000

EASD 2024 Hot Topics: The Value of Patient Engagement in the Light of Modern Treatments

10/09/2024

alexa.stelzer Fri, 09/20/2024 - 14:06

Tackling Clinical Inertia in Type 2 Diabetes with Dexcom CGM

About the Presentation

In this presentation from EASD 2024, Prof. Kirsten Nørgaard, MD, DMSc discusses the impact of continuous glucose monitoring (CGM) on managing type 2 diabetes, focusing on the Steno 2 Tech Study. Key findings include improvements in patient engagement, glycemic control, and overall health outcomes.

Key Takeaways:

The presentation highlights key findings from the Steno 2 Tech Study including:

CGM use significantly increases time in range and reduces hemoglobin A1C
Education programs enhance the effectiveness of CGM technology
Positive changes in patient behavior and satisfaction were observed while wearing CGM

Highlights:

00:00:09 Clinical inertia in type 2 diabetes and sensor use
00:01:01 Overview of continuous glucose monitoring (CGM) technology
00:02:03 Introduction to the Steno 2 Tech Study
00:04:44 Case study: Lena’s experience with CGM
00:07:04 Study outcomes: Time in range and weight changes